TY - JOUR
TI - Evaluation of alternative serum biomarkers to monitor the progression of
chronic HBV and HCV infection
AU - Tsiomita, S.
AU - Georgopoulou, U.
AU - Doumba, P. P.
AU - Koskinas, J. and
AU - Adamidis, K.
AU - Papaloukas, C.
AU - Thyphronitis, G.
JO - Infection, Genetics and Evolution
PY - 2018
VL - 58
TODO - null
SP - 17-22
PB - ELSEVIER SCIENCE BV
SN - 1567-1348
TODO - 10.1016/j.meegid.2017.12.002
TODO - Biomarkers; Cirrhosis; HBV/HCV infection; HCC
TODO - Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
are among the most serious health conditions affecting about 600 million
people worldwide leading to a number of severe liver diseases. Due to
the lack of warning signs or mild symptoms during the early stage of the
infection, a molecular signature associated with disease progression
would be useful.
Based on our recent paper where candidate biomarkers were determined
through topological and modularity analysis of protein interaction
networks (PINs), this study was focused on the evaluation of MIF,
TNFRSF1A, FAS and TMSB4X as diagnostic biomarkers in chronic HBV and HCV
infections. The aim was to establish a molecular profile, by combining
those markers, that would discriminate the different stages during the
progression of chronic hepatitis. One hundred and fifteen patients
infected with HBV or HCV categorized into three groups: non-cirrhotic,
cirrhotic and with HCC, and 20 healthy subjects were enrolled in this
study. Serum levels of the aforementioned factors were measured by
ELISA. TNFRSF1A serum levels appeared statistically significantly
increased in all patient groups compared to control group with a p-value
of < 0.05. Furthermore, the combination of TNFRSF1A and TMSB4X serum
levels successfully classified 63, 47% of patients indicating an
association with HBV and HCV infections. Thus, variations of serum
levels of TNFRSF1A and TMSB4X could be associated with the different
stages of the disease and may be utilized for further research. On the
other hand, we found no contribution of MIF and FAS serum levels for
successful classification of patients.
ER -